IMPDH1 and neoplasm: Additionally, our findings elucidate the dysregulation of IMPDH1-regulated purine biosynthesis in high-risk patients, presenting an opportunity for targeted therapy using IMPDH inhibitors to inhibit tumor progression (Fig. 10).